Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis. Read more about Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis.
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment. Read more about Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment.
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Read more about Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. Read more about Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma.
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Read more about CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. Read more about Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Read more about Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Read more about Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.
Vaccinating against cancer: getting to prime time. Read more about Vaccinating against cancer: getting to prime time.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Read more about Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
